Past Symposiums

Session 1: Drug & toxin-induced PH – toxic oil and chemotherapeutic substances

(Chairs: Peter Dorfmüller, Irene Lang, Edda Spiekerkoetter)

8:00 – 8:30     
Cardio-Oncology – A Review
Irene Lang (Vienna)

8:30 – 9:00     
Toxic oil and pathomechanisms
Pilar Escribano-Subias (Madrid)

9:00 – 9:30     
Dasatinib-induced PAH and possible roles of other TKI
Olivier Sitbon (Paris-Saclay)

9:30 – 10:00   
TKI’s & PAH: data from the bench (benefits and risks)        
Christophe Guignabert (Paris-Saclay)

10:00 – 10:30   
Predicting Safer TKI’s Through Transcriptomics
Adam Andruska (Stanford)

10:30 - 11:00
Agents inducing PVOD: alkylating agents and solvents       
Marc Humbert (Paris-Saclay)

11:00 – 11:15 
Discussion

11:15 - 11:30 
Coffee break

Session 2: Drug and toxin-induced pulmonary hypertension – new observations

(Chairs: Gérald Simonneau, Roham Zamanian, Norbert Voelkel)

11:30 – 11:50 
Pediatrics - Diazoxide and PAH
Rachel Hopper (Stanford)

11:50 – 12:10
Could leflunomide and teriflunomide induce PAH?
Jason Weatherald (Edmonton)

12:10 - 12:30 
Chinese herbs & PAH: The Qing Dai / Indirubin data           
Yuichi Tamura (Tokyo)        

12:30 – 12:50
Interferon and direct-acting antivirals
Harm Bogaard (Netherlands)

12:50 – 13:15 
Round Table Discussion
Faculty / UMC / FDA / EMA

13:15 – 13:30 
Summary of the meeting, Adjourn
Roham Zamanian (Stanford)

1:30:pm-2:00pm

What can genotyping PH tell us about disease?
Lessons about vasoreactivity: should we endophenotype all patients?

Anna Hemnes, MD
Vanderbilt University

2:05pm-2:35pm

Applying genomics in other respiratory diseases…what is the best case scenario?

Angela Rogers, MD
Stanford University

2:40pm-3:10pm

How do we apply large scale genotyping to a rare disease? Targeted or broad sequencing?

Tero-Pekka Alastalo, MD, PhD
Blueprint Genetics

3:15pm-3:30pm: BREAK

3:30pm-4:30pm

PANEL DISCUSSION: Identifying the role of Genomics in determining phenotype and treatment responsivity in PAH

Vinicio de Jesus Perez, MD Moderator
Stanford University

Marlene Rabinovitch, MD
Stanford University

Stephen Archer, MD
Queens University, Kingston, Ontario, Canada

Tim Lahm, MD
Indiana University

4:30-5:15pm

Q&A Debrief

Vinicio de Jesus Perez, MD Moderator
Stanford University

Edda Spiekerkoetter, MD
Stanford University

Roham Zamanian, MD
Stanford University

5:30-6:30pm

Reception

Can we apply proteomic technology for phenotyping PH? Can we use 'omic signature to identify treatment responsiveness?

Evangelos Michelakis, MD, FACC, FAHA
University of Alberta

PANEL DISCUSSION: Addressing dilemmas in the application of proteomic technology to pulmonary vascular diseases

Edda Spiekerkoetter, MD Moderator, Mark Nicolls, MD Stanford University, Allan Lawrie, BSc, PhD, The University of Sheffield, England, Steven Kawut, MD, MS, University of Pennsylvania, Todd Bull, MD, University of Colorado

How do we apply large scale genotyping to a rare disease? Targeted or broad sequencing?
 

Tero-Pekka Alastalo, MD, PhD
Blueprint Genetics

12:10pm-1:10pm LUNCH

1:10pm-1:40pm: KEYNOTE TALK

Immunology taught by humans

Mark Davis, PhD
Stanford University

1:40pm-2:00pm

Novel insights into lung autoimmunity through research in rare Mendelian diseases

Anthony Shum, MD
University of California San Francisco

2:00pm-2:20pm

Regulation of pulmonary macrophage function in health and disease

Bruce Trapnell, MD
University of Cincinnati  

2:20pm-2:40pm

A proteomic approach to altered innate and adaptive immunity in the pathogenesis of PAH

Marlene Rabinovitch, MD
Stanford University

2:40pm-3:00pm

Autoantibodies in Systemic Sclerosis-Associated Pulmonary Hypertension

Thomas Medsger, MD
University of Pittsburgh

3:00pm-3:20pm: BREAK

3:20pm-3:40pm

Role of T-Regulatory cells in immune modulation

Maria Grazia Roncarolo, MD
Stanford University

3:40pm-4:00pm

Immunosuppression in the treatment of CTD-PAH

Lorinda Chung, MD
Stanford University

4:00pm-4:30pm: CLINICAL ROUND TABLE

Immunity and PAH: implication for clinical practice

Yon Sung, MD Moderator
Stanford University

Lorinda Chung, MD
Stanford University

Paul Hassoun, MD
Johns Hopkins Medicine

Marc Humbert, MD, PhD
Université Paris-Sud

Roham Zamanian, MD
Stanford University

4:30-5:15pm: Reception

Introduction to immunity and immune dysfunction: what are the key players?

Mark Nicolls, MD
Stanford University

Interface of TH2 inflammation and TGF-beta signaling in pulmonary hypertension

Rubin Tuder, MD
University of Colorado Denver

Is there a causative link between immunity and PAH? A clinical perspective

Ross Metzger, PhD Moderator, Mark Nicolls, MD, Edda Spiekerkoetter, MD, PJ Utz, MD, Stanford University
Steve Abman, MD, University of Colorado Denver, Virginia Steen, MD, Georgetown University

Regulation of pulmonary macrophage function in health and disease

Bruce Trapnell, MD
University of Cincinnati 

Role of T-Regulatory cells in immune modulation

Maria Grazia Roncarolo, MD
Stanford University

12:00-12:10 

Introduction and vision 

Mark Krasnow, MD, PhD
Stanford University

12:10-1:00 

BMPR2 mutations in PH: From discovery to present time 

James Loyd, MD
Vanderbilt University

1:00-1:50 

The BMPR2 pathway: From a basic scientist’s perspective 

Jeff Wrana, PhD
University of Toronto, Canada

1:50-2:00 Break

2:00-2:10 

There must be more BMP pathway genes than BMPR2 involved in PH: What are they and why haven’t they been identified by human genetics?

Dean Li, MD, PhD
University of Utah

2:10-2:30 Panel Discussion 

Micheala Aldred, PhD
Cleveland Clinic

Dean Li, MD, PhD
University of Utah

James West, PhD
Vanderbilt University

2:30-2:40 

What are the most important cellular players in PH? 

Marlene Rabinovitch, MD
Stanford University

2:40-3:00 Panel Discussion 

Nicholas Morrell, MD 
University of Cambridge, England

Marlene Rabinovitch, MD
Stanford University

Kurt Stenmark, MD
University of Colorado Denver

Norbert Voelkel, MD
Virginia Commonwealth University

3:00-3:10

Is BMPR2 important in non-familial forms of PH? 

Vinicio de Jesus Perez, MD
Stanford University

3:10-3:30 Panel Discussion 

Stephen Archer, MD
Queen's Univeristy
Kingston, Ontario, Canada

Euan Ashley, MD, PhD 
Stanford University

David Cornfield, MD 
Stanford University

Vinicio de Jesus Perez, MD
Stanford University

Marc Humbert, MD, PhD
Stanford University

3:30-3:40 Break

3:40-3:50 

Can we detect and trace dysfunctional BMPR2 signaling in vivo? 

Pehr Harbury, PhD
Stanford University

3:50-4:10 Panel Discussion 

Christopher Contag, PhD
Stanford University

Vinicio de Jesus Perez, MD
Stanford University

Pehr Harbury, PhD
Stanford University

4:10-4:20 

Can we modulate the BMPR2 pathway in vivo? 

Edda Spiekerkoetter, MD
Stanford University

4:20-4:40 Panel Discussion 

Edda Spiekerkoetter, MD
Stanford University

Mark Nicolls, MD
Stanford University

4:40-5:00

Lessons for the clinician: How can we apply our knowledge about BMP signaling clinically? 

Colleen Caleshu, ScM, CGC
Stanford University

Jeffrey Feinstein, MD, MPH
Stanford University

Roham Zamanian, MD
Stanford University

5:00-5:30 Reception